{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004700","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.369807+00:00","generated_at":"2026-06-04T02:16:03.368863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ReShape Lifesciences reports FY2023 revenue of $8.7M, down 22.8% as GLP-1 drugs pressure bariatric market","bullets":["FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.","Gross profit $5.5M (63.9% margin vs 60.5% in 2022); sales & marketing expenses cut 46.8% to $7.5M.","Cash $4.5M and debt-free; expects 2024 operating expenses to decrease >50% vs 2023 via further RIF.","Received FDA approval for Lap-Band 2.0 FLEX in Dec 2023; first surgeries completed in Feb 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004700","json":"https://secwatch.observer/filing/0001558370-24-004700.json","markdown":"https://secwatch.observer/filing/0001558370-24-004700.md","text":"https://secwatch.observer/filing/0001558370-24-004700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/0001558370-24-004700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/rsls-20240401x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:16:03.368863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e264fd1c2af232af1d9fb0f66dde155e2081cb5","claim":"Vyome Holdings, Inc reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8.7 million. Guidance reaffirmed.","evidence_excerpt":"Revenue totaled $8.7 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024004700/0001558370-24-004700-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$8.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}